Schedule 13D - Amendment No. 2
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2 )*
SPECTRUM PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
(CUSIP Number)
Rajesh C. Shrotriya
Spectrum Pharmaceuticals, Inc.
157 Technology Drive
Irvine, CA 92618
(949) 788-6700
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| |
|
|
|
|
|
| 1 |
|
NAMES OF REPORTING PERSONS
Rajesh C. Shrotriya |
| |
|
|
| |
|
|
| 2 |
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
| |
(a) o |
| |
(b) o |
| |
|
|
| 3 |
|
SEC USE ONLY |
| |
|
| |
|
| |
|
|
| 4 |
|
SOURCE OF FUNDS (SEE INSTRUCTIONS) |
| |
|
| |
PF |
| |
|
|
| 5 |
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |
| |
|
| |
o |
| |
|
|
| 6 |
|
CITIZENSHIP OR PLACE OF ORGANIZATION |
| |
|
| |
United States
|
| |
|
|
|
| |
7 |
|
SOLE VOTING POWER |
| |
|
|
| NUMBER OF |
|
2,198,259 |
| |
|
|
|
| SHARES |
8 |
|
SHARED VOTING POWER |
| BENEFICIALLY |
|
|
| OWNED BY |
|
515,000 |
| |
|
|
|
| EACH |
9 |
|
SOLE DISPOSITIVE POWER |
| REPORTING |
|
|
| PERSON |
|
2,198,259 |
| |
|
|
|
| WITH |
10 |
|
SHARED DISPOSITIVE POWER |
| |
|
|
| |
|
515,000 |
| |
|
|
| 11 |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| |
|
| |
2,713,259 |
| |
|
|
| 12 |
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) |
| |
|
| |
o
|
| |
|
|
| 13 |
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) |
| |
|
| |
7.80%1 |
| |
|
|
| 14 |
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) |
| |
|
| |
IN |
1 The percentage owned is based on 32,995,887 shares of common stock outstanding as of May 6, 2009.
2
EXPLANATORY NOTE: Dr. Rajesh C. Shrotriya previously filed a statement of beneficial ownership, and
amendments thereto, with the Securities and Exchange Commission (the “SEC”) with respect to the
common stock, par value $0.001 per share (the “Common Stock”), of Spectrum Pharmaceuticals, Inc.
(the “Company”) on Schedule 13D pursuant to Section 13(d) of the Securities Exchange Act of 1934,
as amended (the “Act”), and Rule 13d-1 thereunder. Due to a recent tender of stock options and
subsequent purchase of Common Stock of the Company, Dr. Shrotriya’s beneficial ownership changed by
more than one per cent of the number of issued and outstanding shares of Common Stock, thereby
requiring the filing of this statement on Schedule 13D with the SEC pursuant to Section 13(d) of
the Act and Rule 13d-1 thereunder.
Item 1. Security and Issuer
This Schedule 13D (the “Statement”) relates to the Common Stock of the Company that is
beneficially owned by Dr. Shrotriya. The Company’s principal executive offices are located at 157
Technology Drive, Irvine, CA 92618.
Item 2. Identity and Background
| (a) |
|
Rajesh C. Shrotriya |
| |
| (b) |
|
Dr. Shrotriya’s business address is 157 Technology Drive, Irvine, CA 92618. |
| |
| (c) |
|
Dr. Shrotriya is the Chairman of the Board, Chief Executive Officer and
President of the Company. The Company is a biopharmaceutical company that
acquires, develops and commercializes a diversified portfolio of drug
products, with a focus on oncology, urology and other critical health
challenges. The Company’s principal executive offices are located at 157
Technology Drive, Irvine, CA 92618. |
| |
| (d) |
|
During the last five years, Dr. Shrotriya has not been convicted in a
criminal proceeding (excluding traffic violations or similar
misdemeanors). |
| |
| (e) |
|
During the last five years, Dr. Shrotriya has not been a party to a civil
proceeding of a judicial or administrative body of competent jurisdiction
and as a result of such proceeding been or been subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, federal or state securities laws or
finding any violation with respect to such laws. |
| |
| (f) |
|
Dr. Shrotriya is a citizen of the United States of America. |
3
Item 3. Source and Amount of Funds or Other Consideration
Dr. Shrotriya beneficially owns 2,713,259 shares of Common Stock of which, (a) 498,920 shares
were purchased by Dr. Shrotriya though open market purchases, an exercise of stock options and the
purchase of shares of common stock under the Company’s Shelf Registration Statement on Form S-3
(File No. 333-150260), in each case with his personal funds; (b) 420,000 shares were acquired upon
the grant of restricted stock, subject to future vesting, as compensation, in each case, granted by
the Company to Dr. Shrotriya without the expenditure of his personal funds, except for payment of
taxes upon the vesting of such restricted stock; (c) 17,339 shares were acquired through 401(k)
matching contributions made by the Company in shares; and (d) 1,777,000 shares reported as
beneficially owned in this Schedule 13D represent shares that Dr. Shrotriya has the right to
acquire within 60 days through the exercise of the currently vested portions of stock options
granted to him by the Company, for which no funds have yet been expended by Dr. Shrotriya.
Item 4. Purpose of Transaction
Dr. Shrotriya owns securities of the Company for investment and compensatory purposes.
Other than any shares or other securities of the Company that Dr. Shrotriya may receive as
compensation from the Company, Dr. Shrotriya does not presently have any definitive plan that
relates to or would result in any of the items listed under (A) — (J) of this item. In his
capacity as Chairman of the Board of Directors, Chief Executive Officer and President of the
Company Dr. Shrotriya has an active role in the Company’s management and therefore, may have
general knowledge about one or more of the items listed under (A) — (J) of this item.
Item 5. Interest in Securities of the Issue
(a) As of May 6, 2009, Dr. Shrotriya beneficially owns an aggregate of 2,713,259 shares,
representing an aggregate of 7.80% of the outstanding shares of Common Stock.
(b) Dr. Shrotriya has shared voting and dispositive power over 515,000 of the shares with his
wife, Chitra Shrotriya, whose identifying information is provided below:
Chitra Shrotriya
Mrs. Shrotriya’s business address is 157 Technology Drive, Irvine, CA 92618.
Mrs. Shrotriya is the wife of Dr. Shrotriya, who is the Chairman of the Board, Chief Executive
Officer and President of the Company. The Company is a biopharmaceutical company that acquires,
develops and commercializes a diversified portfolio of drug products, with a focus on oncology,
urology and other critical health challenges. The Company’s principal executive offices are located
at 157 Technology Drive, Irvine, CA 92618.
During the last five years, Mrs. Shrotriya has not been convicted in a criminal proceeding
(excluding traffic violations or similar misdemeanors).
During the last five years, Mrs. Shrotriya has not been a party to a civil proceeding of a judicial
or administrative body of competent jurisdiction and as a result of such proceeding been or been
subject to a judgment, decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, federal or state securities laws or finding any violation with
respect to such laws.
Mrs. Shrotriya is a citizen of the United States of America.
4
(c) Transactions by Dr. Shrotriya that were effected during the past 60 days are as follows:
On April 29, 2009 and May 5, 2009, Dr. Shrotriya purchased an aggregate of 60,000 shares of
common stock of the Company on the open market at an average price of $2.48 per share.
On May 6, 2009, Dr. Shrotriya purchased 290,000 shares of common stock at a price of $2.70 per
share directly from the Company under the Company’s shelf registration statement.
(d) — (e) Not Applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of
the Issuer
Not Applicable.
Item 7. Material to Be Filed as Exhibits
Not Applicable.
5
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the
information set forth in this statement is true, complete and correct.
Date:
June 23, 2009
| |
|
|
|
|
| |
|
|
| |
/s/ Rajesh C. Shrotriya
|
|
| |
Rajesh C. Shrotriya |
|
| |
|
|
| |
6